Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27696084
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 J+Thromb+Thrombolysis
2017 ; 43
(2
): 166-171
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Safe and effective use of rivaroxaban for treatment of cancer-associated venous
thromboembolic disease: a prospective cohort study
#MMPMID27696084
Mantha S
; Laube E
; Miao Y
; Sarasohn DM
; Parameswaran R
; Stefanik S
; Brar G
; Samedy P
; Wills J
; Harnicar S
; Soff GA
J Thromb Thrombolysis
2017[Feb]; 43
(2
): 166-171
PMID27696084
show ga
Low-molecular weight heparin (LMWH) has been the standard of care for treatment
of venous thromboembolism (VTE) in patients with cancer. Rivaroxaban was approved
in 2012 for the treatment of pulmonary embolism (PE) and deep vein thrombosis
(DVT), but no prior studies have been reported specifically evaluating the
efficacy and safety of rivaroxaban for cancer-associated thrombosis (CAT). Under
a Quality Assessment Initiative (QAI), we established a Clinical Pathway to guide
rivaroxaban use for CAT and now report a validation analysis of our first 200
patients. A 200 patient cohort with CAT (PE or symptomatic, proximal DVT), whose
full course of anticoagulation was with rivaroxaban, were accrued. In competing
risk analysis, primary endpoints at 6 months included new or recurrent PE or
symptomatic proximal lower extremity DVT, major bleeding, clinically-relevant
non-major bleeding leading to discontinuation of rivaroxaban, or death. In
competing risk analysis, the 6 months cumulative incidence of new or recurrent
VTE was 4.4?% (95?% CI?=?1.4-7.4?%), major bleeding was 2.2?% (95?% CI?=?0-4.2?%)
and all-cause mortality 17.6?% (95?% CI?=?11.7-23.0?%). In this cohort of 200
patients with active cancer and CAT the rates of new or recurrent VTE and major
bleeding were comparable to the cancer subgroup analysis from the EINSTEIN
studies. The results of our Clinical Pathway provide guidance on Rivaroxaban use
for treatment of CAT, and suggest that safety and efficacy is preserved, compared
with past-published experience with LMWH.
free
free
free
